JP2024109616A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024109616A5 JP2024109616A5 JP2024074184A JP2024074184A JP2024109616A5 JP 2024109616 A5 JP2024109616 A5 JP 2024109616A5 JP 2024074184 A JP2024074184 A JP 2024074184A JP 2024074184 A JP2024074184 A JP 2024074184A JP 2024109616 A5 JP2024109616 A5 JP 2024109616A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- cxcr4
- gpcrx
- pharmaceutical composition
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607876P | 2017-12-19 | 2017-12-19 | |
| US62/607,876 | 2017-12-19 | ||
| US201862679598P | 2018-06-01 | 2018-06-01 | |
| US62/679,598 | 2018-06-01 | ||
| US201862732946P | 2018-09-18 | 2018-09-18 | |
| US62/732,946 | 2018-09-18 | ||
| JP2020535043A JP7517986B2 (ja) | 2017-12-19 | 2018-12-18 | Ｇｐｃｒヘテロマー阻害剤及びその用途 |
| PCT/KR2018/016166 WO2019124951A1 (en) | 2017-12-19 | 2018-12-18 | Gpcr heteromer inhibitors and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020535043A Division JP7517986B2 (ja) | 2017-12-19 | 2018-12-18 | Ｇｐｃｒヘテロマー阻害剤及びその用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024109616A JP2024109616A (ja) | 2024-08-14 |
| JP2024109616A5 true JP2024109616A5 (https=) | 2024-12-03 |
| JP7818648B2 JP7818648B2 (ja) | 2026-02-20 |
Family
ID=66813757
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020535043A Active JP7517986B2 (ja) | 2017-12-19 | 2018-12-18 | Ｇｐｃｒヘテロマー阻害剤及びその用途 |
| JP2024074184A Active JP7818648B2 (ja) | 2017-12-19 | 2024-05-01 | Ｇｐｃｒヘテロマー阻害剤及びその用途 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020535043A Active JP7517986B2 (ja) | 2017-12-19 | 2018-12-18 | Ｇｐｃｒヘテロマー阻害剤及びその用途 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10709763B2 (https=) |
| EP (2) | EP3727371A4 (https=) |
| JP (2) | JP7517986B2 (https=) |
| KR (2) | KR20260035212A (https=) |
| CN (1) | CN111741752A (https=) |
| AU (1) | AU2018388302B2 (https=) |
| BR (1) | BR112020012075A2 (https=) |
| CA (1) | CA3086337A1 (https=) |
| TW (1) | TWI818938B (https=) |
| WO (1) | WO2019124951A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3727371A4 (en) | 2017-12-19 | 2021-10-27 | GPCR Therapeutics, Inc. | GPCR HETEROMER INHIBITORS AND THEIR USES |
| MX2020009286A (es) | 2018-03-05 | 2020-12-11 | Teon Therapeutics Inc | Antagonistas del receptor de adenosina y usos de los mismos. |
| CA3129314A1 (en) * | 2019-03-06 | 2020-09-10 | Vikramaditya Ganapati Yadav | Compositions and methods for biosynthesis of terpenoids or cannabinoids in a heterologous system |
| BR112021022887A2 (pt) * | 2019-05-17 | 2022-01-18 | Gpcr Therapeutics Inc | Inibidores de heterômero gpcr e usos dos mesmos |
| KR102268983B1 (ko) * | 2019-09-11 | 2021-06-24 | 경북대학교 산학협력단 | 엔도테린 수용체 억제제에 의한 엑소좀 분비 억제 또는 pd-l1 발현 억제 용도 |
| CN110755431B (zh) * | 2019-11-08 | 2023-02-28 | 暨南大学 | 地氯雷他定在制备抗肝癌药物中的应用 |
| WO2022025168A1 (ja) * | 2020-07-30 | 2022-02-03 | 国立大学法人広島大学 | 凝固・線溶系と補体を介したマスト細胞および好塩基球の活性化の制御ならびにその医薬用途 |
| CN116057185A (zh) | 2020-08-15 | 2023-05-02 | 雷杰纳荣制药公司 | 治疗具有编码降钙素受体(calcr)的变体核酸分子的受试者的肥胖症 |
| CN112807425A (zh) * | 2021-01-14 | 2021-05-18 | 南方医科大学深圳医院 | 一种tTIM融合蛋白疫苗、制备方法及应用 |
| WO2023010330A1 (zh) * | 2021-08-04 | 2023-02-09 | 杭州浙大迪迅生物基因工程有限公司 | 一种人组胺受体HRH1 mRNA检测引物探针组、试剂盒和检测方法 |
| CN114574580B (zh) * | 2022-02-14 | 2022-11-29 | 山东大学 | 靶向a2br联合化疗在三阴性乳腺癌治疗中的应用 |
| WO2023211779A1 (en) * | 2022-04-25 | 2023-11-02 | Kallyope, Inc. | Treatment of headache disorders with nk3 modulators |
| CA3258771A1 (en) * | 2022-06-10 | 2023-12-14 | Gpcr Therapeutics, Inc. | GPCR INHIBITORS AND THEIR USES |
| CN114891742B (zh) * | 2022-06-23 | 2024-06-04 | 杭州中赢生物医疗科技有限公司 | 一种强杀伤性nk细胞的培养基及体外扩增方法 |
| CN116298305B (zh) * | 2023-01-03 | 2024-05-28 | 郑州大学 | 一种抗nt5c1a自身抗体检测方法及体外诊断试剂盒 |
| EP4698530A1 (en) | 2023-04-18 | 2026-02-25 | Kallyope, Inc. | Nk3 modulators and uses thereof |
| AU2024334309A1 (en) * | 2023-08-30 | 2026-03-05 | Josephine Cardarelli | Gpcr inhibitors and uses thereof |
| CN119345201B (zh) * | 2024-12-25 | 2025-03-18 | 中国人民解放军总医院第三医学中心 | 治疗tfe3基因重排性肾细胞癌的药物或药物组合物及用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3705097A (en) | 1996-07-01 | 1998-01-21 | Biosignal Inc. | Peptides and peptidomimetic compounds affecting the activity of g-protein-coupled receptors by altering receptor oligomerization |
| AU3249997A (en) | 1996-07-01 | 1998-01-21 | Biosignal Inc. | Method of assaying compounds which affect the activity of g protein-coupled receptors based on measurement of receptor oligomerization |
| US6855807B1 (en) | 1999-06-16 | 2005-02-15 | New York University | Heterodimeric opioid G-protein coupled receptors |
| US20010053848A1 (en) | 2000-03-10 | 2001-12-20 | Patel Yogesh C. | Hetero-oligomeric G protein-coupled receptors as novel drug targets |
| DK1411918T3 (da) * | 2001-07-31 | 2012-04-23 | Genzyme Global S A R L | Fremgangsmåder til at mobilisere progenitor/stamceller |
| ATE500270T1 (de) | 2003-05-20 | 2011-03-15 | Univ Glasgow | Materialien und methoden die sich auf g-protein gekoppelte rezeptor oligomere beziehen |
| WO2005103721A1 (en) | 2004-04-20 | 2005-11-03 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 4 (cxcr4) |
| CA2640087A1 (en) * | 2006-01-25 | 2007-08-02 | Mount Sinai School Of Medicine | Methods and compositions for modulating the mobilization of stem cells |
| US20090028832A1 (en) * | 2006-08-10 | 2009-01-29 | Chung Leland F | Compositions and methods for targeted tumor therapy |
| EP2285833B1 (en) | 2008-05-16 | 2014-12-17 | Ablynx N.V. | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
| WO2010002468A1 (en) | 2008-07-01 | 2010-01-07 | The Trustees Of Columbia University In The City Of New York | A functional complementation assay for defined gpcr oligomers |
| FR2949156B1 (fr) | 2009-08-13 | 2016-04-15 | Cis-Bio Int | Methode de determination de la liaison d'un compose donne a un recepteur membranaire |
| US9216189B2 (en) | 2010-01-25 | 2015-12-22 | Icahn School Of Medicine At Mount Sinai | Antibodies which bind type I cannabinoid receptor/angiotensis II receptor heteromers |
| JP2011168567A (ja) * | 2010-02-22 | 2011-09-01 | Kyoto Univ | 再発癌の予防または治療用医薬 |
| KR101029972B1 (ko) | 2010-06-18 | 2011-04-20 | 서울대학교산학협력단 | 바이러스 벡터를 이용하여 단백질의 상호작용을 측정하는 방법 |
| WO2012047339A2 (en) * | 2010-06-28 | 2012-04-12 | The General Hospital Corporation | Anti-cxcr4 as a sensitizer to cancer therapeutics |
| US9267934B2 (en) * | 2010-10-26 | 2016-02-23 | University Of South Alabama | Methods and compositions for ameliorating pancreatic cancer |
| CA2919790C (en) * | 2013-08-02 | 2018-06-19 | Pfizer Inc. | Anti-cxcr4 antibodies and antibody-drug conjugates |
| CA2920377A1 (en) * | 2013-08-05 | 2015-02-12 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| CN103536594A (zh) * | 2013-10-21 | 2014-01-29 | 江苏亚虹医药科技有限公司 | G蛋白偶联受体拮抗剂在用于制备治疗谷氨酸受体高表达肿瘤药物中的用途 |
| CA2970012C (en) | 2013-12-23 | 2022-07-19 | Universite De Montreal | Systems and methods for the monitoring of protein complex formation in cells |
| ES2924394T3 (es) * | 2015-01-09 | 2022-10-06 | Adalta Ltd | Moléculas de unión a CXCR4 |
| WO2017020128A1 (en) * | 2015-08-03 | 2017-02-09 | Université de Montréal | Markers for acute myeloid leukemias with core binding factor rearrangements and other genetic subtypes and uses thereof |
| EP3727371A4 (en) | 2017-12-19 | 2021-10-27 | GPCR Therapeutics, Inc. | GPCR HETEROMER INHIBITORS AND THEIR USES |
-
2018
- 2018-12-18 EP EP18892135.7A patent/EP3727371A4/en active Pending
- 2018-12-18 AU AU2018388302A patent/AU2018388302B2/en active Active
- 2018-12-18 EP EP21174644.1A patent/EP3900712A1/en active Pending
- 2018-12-18 JP JP2020535043A patent/JP7517986B2/ja active Active
- 2018-12-18 US US16/224,450 patent/US10709763B2/en active Active
- 2018-12-18 CN CN201880089801.6A patent/CN111741752A/zh active Pending
- 2018-12-18 CA CA3086337A patent/CA3086337A1/en active Pending
- 2018-12-18 WO PCT/KR2018/016166 patent/WO2019124951A1/en not_active Ceased
- 2018-12-18 TW TW107145764A patent/TWI818938B/zh active
- 2018-12-18 KR KR1020267002674A patent/KR20260035212A/ko active Pending
- 2018-12-18 BR BR112020012075-8A patent/BR112020012075A2/pt unknown
- 2018-12-18 KR KR1020207019080A patent/KR20200103018A/ko not_active Ceased
-
2020
- 2020-05-27 US US16/885,196 patent/US11857600B2/en active Active
-
2021
- 2021-04-16 US US17/233,359 patent/US20210268069A1/en not_active Abandoned
-
2024
- 2024-05-01 JP JP2024074184A patent/JP7818648B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024109616A5 (https=) | ||
| JP2021507925A5 (https=) | ||
| Magnaghi et al. | Afatinib is a new therapeutic approach in chordoma with a unique ability to target EGFR and brachyury | |
| Nakagawa et al. | Immunohistochemical KIT (CD117) expression in thymic epithelial tumors | |
| Pernis et al. | Interleukin 4 signals through two related pathways. | |
| US20130330765A1 (en) | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies | |
| MX2013010581A (es) | Receptor del factor de crecimiento de fibroblastos (fgfr) y ligandos del mismo como biomarcadores para cancer de mama en sujetos hr positivos. | |
| JP2009092508A (ja) | リウマチ治療剤の効果の予測方法 | |
| US20150361504A1 (en) | Biomarker for predicting response of cll to treatment with a btk inhibitor | |
| McLeskey et al. | Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors. | |
| Sabah et al. | The problem with KIT: clinical implications and practical difficulties with CD117 immunostaining | |
| Aguayo et al. | Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL) | |
| Dias-Santagata et al. | A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas | |
| Lee et al. | Genetic analysis of ovarian microcystic stromal tumor | |
| Sequeira et al. | The oral and skin pathergy test | |
| KR20210110664A (ko) | Tam 및 met 키나제의 억제제로서의 퀴놀린 화합물 | |
| KR20230147136A (ko) | Raf 억제제와 mek 억제제의 조합 | |
| Hornick et al. | The significance of KIT (CD117) in gastrointestinal stromal tumors | |
| Koyama et al. | Recurrent gastrointestinal stromal tumor (GIST) of the stomach associated with a novel c-kit mutation after imatinib treatment | |
| Kang et al. | Extragastrointestinal stromal tumor presenting as a scrotal mass: an unusual case | |
| US10426777B2 (en) | Methods used to treat cancer | |
| Potti et al. | Immunohistochemical identification of HER-2/neu overexpression and CD117 (c-kit) expression in multiple myeloma | |
| JP2008515459A (ja) | オートクライン成長因子受容体および方法 | |
| Khrais et al. | Primary cutaneous anaplastic large cell lymphoma with gastric metastasis | |
| Ananthaswamy et al. | Correlation between Ha-ras gene amplification and spontaneous metastasis in NIH 3T3 cells transfected with genomic DNA from human skin cancers |